Peter W. PENG, Author at MediaMedic

ESMO Exclusive Interview | Professor Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression

By Peter W. PENG 2023.11.17

The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Oncology Frontier team delved into the frontline, capturing international advancements and witnessing the strides made by China in the global oncology arena. Professor Changsong Qi from Peking University Cancer Hospital delivered a crucial oral presentation (Abstract No: 1018O) at this conference. In an exclusive interview with Oncology Frontier, Professor Qi shared insights from his reported research and thoughts on colorectal cancer studies presented at this year's ESMO. This article compiles relevant content for readers.

ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients

By Peter W. PENG 2023.11.17

The monarchE study is a randomized, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of abemaciclib combined with endocrine therapy versus endocrine therapy alone in HR+, HER2-high-risk early-stage breast cancer patients. Since the disclosure of relevant data in March 2020, the study results have been updated multiple times, establishing the standard position of abemaciclib combined with endocrine therapy. At the 2023 ESMO Congress, Professor Nadia Harbeck, the lead investigator of the monarchE study from the University of Munich, Germany, announced the milestone data results of the 5-year follow-up. In this regard, Professor Zhimin Shao, the lead investigator of the monarchE study, director of the Institute of Oncology and Institute of Breast Cancer Research at Fudan University, and director of the Department of Surgery at Fudan University Affiliated Tumor Hospital, provided an introduction and interpretation of the monarchE study results.

ESMO Hot Topic | Professor Xinan Sheng: HIF-2α Inhibitor Offers New Targeted Treatment Option for Advanced Renal Clear Cell Carcinoma Patients

By Peter W. PENG 2023.11.17

The treatment of advanced renal clear cell carcinoma (ccRCC) has evolved from the cytokine era to the era of targeted therapy, immunotherapy, and immunotherapy combinations, expanding survival options for patients. However, results from the CONTACT-03 study suggest that continuing with immunotherapy combinations after immunotherapy failure may not be a preferred option, highlighting the need for exploration of subsequent treatment options for this patient population. Two significant studies presented at this year's ESMO conference (LBA87, LBA88) [2,3] indicate that, compared to everolimus, the HIF-2α inhibitor Belzutifan significantly improves the PFS and ORR of advanced ccRCC patients. Additionally, Belzutifan in combination with cabozantinib demonstrates persistent anti-tumor activity and safety consistent with previous observations. At the conference, "Oncology Frontier" had the privilege of inviting Professor Xinan Sheng from Peking University Cancer Hospital to provide in-depth insights.

ESMO Highlights | Professor WeiYu’s Commentary on Advances in Neoadjuvant Therapy and Bladder Preservation in Bladder Cancer

By Peter W. PENG 2023.11.17

Bladder cancer is a common tumor in the urinary system, with muscle-invasive bladder cancer (MIBC) accounting for approximately 20% of all bladder cancers. Nearly half of non-muscle-invasive bladder cancer (NMIBC) patients may relapse into MIBC. Currently, various explorations in neoadjuvant therapy, including chemotherapy, immunotherapy, and their combination, have been conducted. The recent ESMO conference revealed several advancements in research. Professor Wei Yu from Peking University First Hospital shares the latest developments in neoadjuvant therapy and bladder preservation for bladder cancer.

ESMO 2023 | Professor Zhongsheng Tong: New Trop-2 ADC Brings New Hope for HR+/HER2- Advanced Breast Cancer Patients

By Peter W. PENG 2023.11.16

According to the cancer burden data released by the World Health Organization, hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 60%. The treatment strategies and survival benefits for first-line and subsequent-line therapy for HR+/HER2- advanced breast cancer have been a hot topic. The TROPION-Breast01 study data, unveiling the promising results of the new ADC drug Dato-DXd in the field of HR+/HER2- advanced breast cancer, were disclosed at this year's ESMO conference. Professor Zhongsheng Tong from Tianjin Medical University Cancer Hospital, a prominent figure in the field, interprets the findings for Oncology Frontier.

ESMO China Voice | Professor Xiaohua Wu’s Team Presents Two LBA Studies at ESMO, Adding Chinese Solutions to Gynecological Cancer Treatment

By Peter W. PENG 2023.11.16

On October 20, the 2023 European Society for Medical Oncology (ESMO) Congress officially opened in Madrid, Spain. As one of the most influential global oncology conferences, top experts from around the world gathered to discuss and share the latest international research findings and cancer treatment technologies. Professor Xiaohua Wu's team from Fudan University Affiliated Cancer Hospital presented two significant studies at the ESMO 2023 Late-breaking Abstract (LBA) session, providing important references for clinical practice. "Oncology Frontier" had the privilege of inviting Professor Xiaohua Wu to share the research findings on-site.

ESMO 2023: EGFR-MET Dual-Specific Antibody Combination Emerges as a New Option for EGFR-Mutant Advanced NSCLC

By Peter W. PENG 2023.11.16

According to the reports from Phase III MARIPOSA and MARIPOSA-2 trials presented at the 2023 ESMO Presidential Symposium, Amivantamab combination therapy demonstrated clinically significant improvements in both first-line and second-line treatments compared to standard therapy (Abstract Numbers LBA14 and LBA15).

ESMO in Five Minutes | Prof. Haitao Zhao : Highlights of Advances in the Treatment of Cholangiocarcinoma

By Peter W. PENG 2023.11.16

Fibroblast Growth Factor Receptor inhibitors (FGFRi) have been shown to play a role in the treatment of cholangiocarcinoma (CCA) with FGFR alterations after chemotherapy. However, disease progression occurs after 6-8 months. Secondary multiclonal mutations in the FGFR2 kinase domain represent a notable acquired resistance mechanism. Tinengotinib is identified as a novel FGFRi with high efficacy against various FGFR2 kinase domain mutations and has shown promising clinical results in CCA patients previously treated with FGFRi. This study presents summary data from three trials.

AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

By Peter W. PENG 2023.11.14

From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are extended here! The Beijing University People's Hospital and Peking University Hepatology Institute team achieved 1 oral and 9 poster presentations on scientific research in the fields of hepatic encephalopathy, fatty liver, hepatitis C, hepatitis B, and liver cancer. Some research abstracts are shared below, and "Hepatology Digest" takes you to appreciate the team's excellence.

AASLD2023 | Unveiling the Four Prestigious “Distinguished Awards” on the First Day of the Conference!

By Peter W. PENG 2023.11.14

From November 10th to 14th, the grand finale of the international hepatology scene, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023, unfolded in Boston, USA. AASLD, in its annual tradition, awarded the "Distinguished Awards" during the conference to honor peers who have made significant strides in the field of hepatology. The recipients of the coveted 2023 "Distinguished Awards" were announced on the conference's inaugural day (local time, November 10th).